UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
28.13
-0.56 (-1.95%)
May 29, 2026, 4:00 PM EDT - Market closed
UroGen Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 140.49 | 109.79 | 90.4 | 82.71 | 64.36 | 48.04 | |
Revenue Growth (YoY) | 52.92% | 21.45% | 9.29% | 28.52% | 33.96% | 307.17% |
Cost of Revenue | 14.26 | 12.45 | 8.88 | 9.36 | 7.65 | 5.16 |
Gross Profit | 126.24 | 97.34 | 81.52 | 73.35 | 56.7 | 42.89 |
Selling, General & Admin | 171.62 | 155.1 | 121.15 | 93.27 | 82.84 | 87.54 |
Research & Development | 62.83 | 67.11 | 57.15 | 45.61 | 52.91 | 47.64 |
Total Operating Expenses | 234.45 | 222.2 | 178.3 | 138.89 | 135.74 | 135.18 |
Operating Income | -108.21 | -124.86 | -96.78 | -65.54 | -79.04 | -92.29 |
Interest Income | 3.79 | 5.3 | 8.67 | 3.48 | 1.01 | 0.21 |
Interest Expense | -33.89 | -33.85 | -35.93 | -36.27 | -30 | -17.29 |
Total Non-Operating Income (Expense) | -30.1 | -28.55 | -27.26 | -32.79 | -28.99 | -17.08 |
Pretax Income | -138.31 | -153.42 | -124.04 | -98.32 | -108.03 | -109.37 |
Provision for Income Taxes | -5.09 | 0.08 | 2.83 | 3.92 | 1.76 | 1.45 |
Net Income | -133.23 | -153.49 | -126.87 | -102.24 | -109.78 | -110.82 |
Net Income to Common | -133.23 | -153.49 | -126.87 | -102.24 | -109.78 | -110.82 |
Shares Outstanding (Basic) | 49 | 48 | 43 | 29 | 23 | 22 |
Shares Outstanding (Diluted) | 49 | 48 | 43 | 29 | 23 | 22 |
Shares Change (YoY) | 7.41% | 12.22% | 48.70% | 26.43% | 2.05% | 2.60% |
EPS (Basic) | -2.75 | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
EPS (Diluted) | -2.75 | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
Shares Outstanding | 48.71 | 48.35 | 42.23 | 32.49 | 23.13 | 22.46 |
Free Cash Flow | -166.04 | -162.73 | -97.06 | -76.57 | -87.81 | -85.64 |
Free Cash Flow Per Share | -3.40 | -3.38 | -2.26 | -2.66 | -3.85 | -3.83 |
Gross Margin | 89.85% | 88.66% | 90.18% | 88.68% | 88.11% | 89.27% |
Operating Margin | -77.02% | -113.73% | -107.06% | -79.23% | -122.82% | -192.11% |
Profit Margin | -78.05% | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% |
FCF Margin | -118.18% | -148.22% | -107.37% | -92.57% | -136.45% | -178.27% |
EBITDA | -105.65 | -122.45 | -95.6 | -63.83 | -77.22 | -90.52 |
EBITDA Margin | -75.20% | -111.54% | -105.75% | -77.17% | -119.99% | -188.42% |
EBIT | -108.21 | -124.86 | -96.78 | -65.54 | -79.04 | -92.29 |
EBIT Margin | -77.02% | -113.73% | -107.06% | -79.23% | -122.82% | -192.11% |
Effective Tax Rate | 3.68% | -0.05% | -2.28% | -3.99% | -1.62% | -1.32% |